GSK sees profit soar on consumer health spinoff

Published On 2023-02-01 04:00 GMT   |   Update On 2023-02-01 11:55 GMT

London: British pharmaceutical giant GlaxoSmithKline on Wednesday announced soaring annual profits thanks to the demerger of its consumer healthcare unit Haleon.Net profit surged to £14.9 billion ($18.3 billion) last year from £4.4 billion in 2021, GSK said in a statement.GSK posted a gain of £10.1 billion thanks to the demerger of Haleon, which became London's biggest listing for more than...

Login or Register to read the full article

London: British pharmaceutical giant GlaxoSmithKline on Wednesday announced soaring annual profits thanks to the demerger of its consumer healthcare unit Haleon.

Net profit surged to £14.9 billion ($18.3 billion) last year from £4.4 billion in 2021, GSK said in a statement.
GSK posted a gain of £10.1 billion thanks to the demerger of Haleon, which became London's biggest listing for more than a decade when it was spun off last year.
The company profited last year also from strong sales of its drugs, notably its shingles vaccine Shingrix.
Total annual group revenue jumped 19 percent to £29.3 billion.
"2022 was a landmark year for GSK delivering the step change in performance we committed to, driven by strong growth in speciality medicines and vaccines, including record sales for Shingrix," GSK chief executive Emma Walmsley said in the earnings statement.
"We enter 2023 with good momentum."
Following the update, GSK's share price rose 0.4 percent to £14.28 on London's top tier FTSE 100 index, which was up 0.1 percent overall in early trading.
"Today's full year results would appear to suggest that the business is heading in the right direction with fourth-quarter profits beating expectations," noted Michael Hewson, chief market analyst at CMC Markets UK.

Read also: WuXi Biologics, GSK enter into license agreement on multiple novel Bi- & Multi-specific T cell engagers

Tags:    
Article Source : AFP

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News